X0M1 Stock Overview
Operates as a biotech royalty aggregator in the United States and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
XOMA Royalty Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.60 |
| 52 Week High | US$32.40 |
| 52 Week Low | US$20.40 |
| Beta | 0.87 |
| 1 Month Change | -16.90% |
| 3 Month Change | -1.67% |
| 1 Year Change | 63.89% |
| 3 Year Change | 15.69% |
| 5 Year Change | -6.65% |
| Change since IPO | -76.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| X0M1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -7.1% | -3.5% | -2.0% |
| 1Y | 63.9% | -14.7% | 6.9% |
Return vs Industry: X0M1 exceeded the German Biotechs industry which returned -14.7% over the past year.
Return vs Market: X0M1 exceeded the German Market which returned 6.9% over the past year.
Price Volatility
| X0M1 volatility | |
|---|---|
| X0M1 Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: X0M1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: X0M1's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 13 | Owen Hughes | xoma.com |
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
XOMA Royalty Corporation Fundamentals Summary
| X0M1 fundamental statistics | |
|---|---|
| Market cap | €306.37m |
| Earnings (TTM) | -€33.96m |
| Revenue (TTM) | €20.71m |
14.8x
P/S Ratio-9.0x
P/E RatioIs X0M1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| X0M1 income statement (TTM) | |
|---|---|
| Revenue | US$21.61m |
| Cost of Revenue | US$2.04m |
| Gross Profit | US$19.57m |
| Other Expenses | US$55.00m |
| Earnings | -US$35.43m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.01 |
| Gross Margin | 90.58% |
| Net Profit Margin | -164.00% |
| Debt/Equity Ratio | 139.0% |
How did X0M1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 17:01 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
XOMA Royalty Corporation is covered by 17 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ritu Baral | Canaccord Genuity |
| Jason Kantor | Credit Suisse |
| Joseph Pantginis | H.C. Wainwright & Co. |